Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Public ClinicalTrials.gov record NCT00969150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Study identification
- NCT ID
- NCT00969150
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Forest Laboratories
- Industry
- Enrollment
- 362 participants
Conditions and interventions
Conditions
Interventions
- Levomilnacipran ER Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2009
- Primary completion
- Oct 31, 2010
- Completion
- Not listed
- Last update posted
- Oct 24, 2013
Started 2009
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Forest Investigative Site | Scottsdale | Arizona | 85254 | — |
| Forest Investigative Site | Encino | California | 91316 | — |
| Forest Investigative Site | Los Alamitos | California | 90720 | — |
| Forest Investigative Site | Oceanside | California | 92056 | — |
| Forest Investigative Site | Denver | Colorado | 80204 | — |
| Forest Investigative Site | Denver | Colorado | 80239 | — |
| Forest Investigative Site | Jacksonville | Florida | 32216 | — |
| Forest Investigative Site | Orlando | Florida | 32806 | — |
| Forest Investigative Site | Chicago | Illinois | 60634 | — |
| Forest Investigative Site | Wichita | Kansas | 67206 | — |
| Forest Investigative Site | Glen Burnie | Maryland | 21061 | — |
| Forest Investigative Site | Fall River | Massachusetts | 02721 | — |
| Forest Investigative Site | East Lansing | Michigan | 48824 | — |
| Forest Investigative Site | Cherry Hill | New Jersey | 08002 | — |
| Forest Investigative Site | Brooklyn | New York | 11235 | — |
| Forest Investigative Site | New York | New York | 10021 | — |
| Forest Investigative Site | Staten Island | New York | 10312 | — |
| Forest Investigative Site 013 | Canton | Ohio | 44718 | — |
| Forest Investigative Site | Dayton | Ohio | 45417 | — |
| Forest Investigative Site | Portland | Oregon | 97210 | — |
| Forest Investigative Site | Philadelphia | Pennsylvania | 19107 | — |
| Forest Investigative Site | Lincoln | Rhode Island | 02865 | — |
| Forest Investigative Site | Woodstock | Vermont | 05091 | — |
| Forest Investigative Site | Bellevue | Washington | 98007 | — |
| Forest Investigative Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00969150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00969150 live on ClinicalTrials.gov.